Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicentre, open-label, post-marketing study to evaluate the safety and efficacy of ripasudil in patients with glaucoma (including SG) or Ocular Hypertension over 2 years

Trial Profile

A prospective, multicentre, open-label, post-marketing study to evaluate the safety and efficacy of ripasudil in patients with glaucoma (including SG) or Ocular Hypertension over 2 years

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ripasudil (Primary)
  • Indications Angle-closure glaucoma; Glaucoma; Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ROCK-J
  • Most Recent Events

    • 12 Feb 2022 Results (n=3374) assessing the long-term safety and effectiveness of ripasudil in Japanese patients with glaucoma or ocular hypertension, published in the Advances in Therapy.
    • 08 Feb 2019 New trial record
    • 04 Jan 2019 Three month interim results (n=3058 safety analysis, n=3016 efficacy analysis) published in the Advances in Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top